NON-LIPIDISED VARIANTS OF NEISSERIA MENINGITIDIS ORF2086 ANTIGENS Russian patent published in 2015 - IPC C07K14/22 A61K39/95 C07K16/12 

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biochemistry, particularly to an immunogenic composition, which induces cross-reactive bacterial antibodies to a number of strains Neisseria meningitidis serotype B. As an active ingredient, the immunogenic composition contains variants of the non-lipidised polypeptide ORF2086 non-functionalised by pyroracemic acid and consisting of an amino acid sequence specified in a group of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO: 20 and SEQ ID NO: 21, wherein the polypeptide contains N-terminal Cys deletion as compared to the existing non-lipidised wild-type polypeptide ORF2086. What is also disclosed is a plasmid, which expresses the non-lipidised polypeptide ORF2086 non-functionalised by pyroracemic acid. What is also disclosed is a method for producing bactericidal antibodies specific to ORF2086 of the sub-family B of the serogroup Neisseria meningitidis in mammals. What is also disclosed is a method for producing the non-lipidised polypeptide ORF2086 non-functionalised by pyroracemic acid.

EFFECT: invention enables inducing the cross-reactive bacterial antibodies to Neisseria meningitidis serotype B.

32 cl, 8 dwg, 14 tbl, 13 ex